Enveda Biosciences
Clinical-stage biotechnology company that uses metabolomics, mass spectrometry, and large-scale machine learning to discover and develop small-molecule medicines derived from natural sources. The organization combines a searchable library of natural-product chemistry, foundation AI models trained on mass spectra, an automated high-throughput laboratory, medicinal chemistry optimization, and clinical development capabilities to advance discovery candidates into human trials.
Industries
Nr. of Employees
medium (51-250)
Enveda Biosciences
Products
Clinical-stage small-molecule therapeutics derived from natural-product discovery
A pipeline of orally dosed small-molecule development candidates discovered via high-throughput metabolomics and machine-learning translation of natural-product chemistry and advanced into IND-enabling studies and early clinical trials.
ENV-6946
ENV-6946 is a first-in-class, gut-preferred, once-daily oral small molecule that offers a multi-biologic in a pill potential via a novel single target for the treatment of inflammatory bowel disease.
ENV-294
ENV-294 is a first-in-class, once-daily oral small molecule with a Dupi-like efficacy and safety profile, with pan-endotype potential in atopic dermatitis and other inflammatory conditions.
ENV-308
ENV-308 is a first-in-class, daily oral small molecule that sustains long-term metabolic health, including maintenance after initial weight loss.
Enveda Platform
An AI-enabled natural-product discovery platform that analyzes natural samples to identify molecules and determine their therapeutic properties at high throughput.
Clinical-stage small-molecule therapeutics derived from natural-product discovery
A pipeline of orally dosed small-molecule development candidates discovered via high-throughput metabolomics and machine-learning translation of natural-product chemistry and advanced into IND-enabling studies and early clinical trials.
ENV-6946
ENV-6946 is a first-in-class, gut-preferred, once-daily oral small molecule that offers a multi-biologic in a pill potential via a novel single target for the treatment of inflammatory bowel disease.
ENV-294
ENV-294 is a first-in-class, once-daily oral small molecule with a Dupi-like efficacy and safety profile, with pan-endotype potential in atopic dermatitis and other inflammatory conditions.
ENV-308
ENV-308 is a first-in-class, daily oral small molecule that sustains long-term metabolic health, including maintenance after initial weight loss.
Enveda Platform
An AI-enabled natural-product discovery platform that analyzes natural samples to identify molecules and determine their therapeutic properties at high throughput.
Services
Collaborative research and partnership models with industry and technology partners to apply AI-driven natural-product discovery workflows to specific therapeutic challenges.
Collaborative research and partnership models with industry and technology partners to apply AI-driven natural-product discovery workflows to specific therapeutic challenges.
Expertise Areas
- Natural product drug discovery
- Metabolomics and mass-spectrometry analytics
- AI / machine learning for chemical structure prediction
- Foundation-model development for scientific data
Key Technologies
- Mass spectrometry (MS/MS)
- Foundation deep-learning models for spectra
- Transformer models for structure prediction
- Automated high-throughput laboratory robotics
News & Updates
Closed a $311 million financing to advance clinical programs, scale the discovery platform and automated laboratory, and advance multiple medicines through clinical development.
Closed an oversubscribed $150M Series D and enrolled the first patient in an early clinical trial for a lead clinical-stage oral candidate.
Announced collaboration with Microsoft for cloud compute resources and revealed PRISM, a foundation model trained on over a billion mass spectra to translate mass spectrometry data into chemical structure and property representations.
Received US FDA IND clearance and initiated a Phase 1 study for an oral small-molecule candidate designed to inhibit multiple gut inflammatory pathways.
Initiated parallel Phase 2a randomized, double-blind, placebo-controlled studies evaluating safety and efficacy in atopic dermatitis and asthma.
Announced the company's first development candidate discovered from natural-product chemistry using AI progressed into a Phase 1 clinical trial following FDA IND clearance.
Closed a $311 million financing to advance clinical programs, scale the discovery platform and automated laboratory, and advance multiple medicines through clinical development.
Closed an oversubscribed $150M Series D and enrolled the first patient in an early clinical trial for a lead clinical-stage oral candidate.
Announced collaboration with Microsoft for cloud compute resources and revealed PRISM, a foundation model trained on over a billion mass spectra to translate mass spectrometry data into chemical structure and property representations.
Received US FDA IND clearance and initiated a Phase 1 study for an oral small-molecule candidate designed to inhibit multiple gut inflammatory pathways.
Initiated parallel Phase 2a randomized, double-blind, placebo-controlled studies evaluating safety and efficacy in atopic dermatitis and asthma.
Announced the company's first development candidate discovered from natural-product chemistry using AI progressed into a Phase 1 clinical trial following FDA IND clearance.